Abd El-Karim et al
Disclosures: Antonio Moreno: Nothing to Disclose, Thomas Issa: Nothing to Disclose, Douglas Farmer: Nothing to Disclose, Edward Wolfgang Lee: Nothing to Disclose 2224 STATIN USE IN CIRRHOSIS CAN DECREASE RISK OF PORTAL HYPERTENSION AND MORTALITY Muhammad Ali Butt 1 Taimur Muzammil 1 Rahul Karna 2 Himsikhar Khataniar 1 Nabeeha Mohy-ud-din 3 , 1 Allegheny General Hospital, Pittsburgh, PA, 2 University of Minnesota Medical Center, 3 Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA Background: MASLD related cirrhosis is one of the leading etiologies of liver disease, and these patients frequently have other comorbidities like atherosclerotic cardiovascular disease (ASCVD), hyperlipidemia (HLD), cerebrovascular disease (CVD), and diabetes mellitus (DM)
Methods: Here we carry out genome-wide association study (GWAS) of 1781 individuals that had undergone bariatric surgery and that also have liver histology
Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications: Part 2
Taking it on an empty stomach with only plain water, and waiting at least 30 minutes before eating, maximises the amount of medication absorbed into the bloodstream